Study of the complexation behaviour of fexofenadine with β-cyclodextrin

Indian Journal of Pharmaceutical Sciences

Volumn 72, Issue 3, 2010, Pages 318-323

  Sapkal, Nidhi ^a   Kilor, Vaishali ^a   Shewale, Bharti D ^d   Bhusari, K P ^b   Daud, A S ^c  

^a Near CP Foundry   (India)

^b Nagar Yuwak Shikshan Sanstha   (India)

^c Zim Laboratories Ltd   (India)

^d H R Patel Women's College of Pharmacy   (India)

Author keywords

cyclodextrin; co precipitation; fexofenadine; inclusion complexes; kneading

Indexed keywords

BETA CYCLODEXTRIN; FEXOFENADINE;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DISSOLUTION; DRUG SOLUBILITY; FEASIBILITY STUDY; IN VITRO SELECTION; INFRARED SPECTROSCOPY; LIQUID; PRECIPITATION; SOLID STATE; X RAY DIFFRACTION;

EID: 77957725509     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.70477     Document Type: Article

References (16)

1. Simpson K, Jarvis B. Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-21.
2. th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 712-3.
3. Qui Y, Zhang G. Research and development of oral forms. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker; 2005. p. 473-5.
4. Faham A, Marechal D, Chenevier P. Inventors; Ethypharm, assignee. Orodispersible tablets containing fexofenadine. United States Patent US 6, 723, 348. Apr. 20, 2004.
5. Wadhwa H, inventor; Ind-Swift Ltd, assignee. Tasteless, directly compressible, fast-dissolving complexes and pharmaceutical formulations thereof. European Patent EP 1454635. Dec. 12, 2007.
6. Illum L, Watts PJ, Cheng YH, inventor; Novel formulations of fexofenadine. United States Patent Application 20010051613. Dec. 12, 2001.
7. Ali SM, Maheshwari A. A Proton Magnetic Resonance Study of Fexofenadine/β-Cyclodextrin Inclusion complexes in aqueous solution. Bull Kor Chem Soc 2005;26:2061-5.
8. Bekers O, Uijtendaal EV, Beijnen JH, Butt A, Underberg WM. Cyclodextrins in the pharmaceutical field. Drug Develop Ind Pharm 1991;17:1503-49.
9. Ammar HO, Nahhas SA Emara LH. Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation. Part 7: Trimethoprim. Pharmazie 1997;52:376-9.
10. Chowdary KP, Buchi NN. Nimesulide and β-cyclodextrin inclusion complexes: physicochemical characterization and dissolution rate studies. Drug Develop Ind Pharm 2000;26:1217-20.
11. Dhanraju MD, Kumaran K, Baskaran T, Moorty MS. Enhancement of bioavailability of griseofulvin by its complexation with β-cyclodextrin. Drug Develop Ind Pharm 1998;24:583-87.
12. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: Drug solubilization and stabilization. J Pharm Sci 1996;85:1017-25.
13. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007;59:645-66.
14. Higuchi T, Connors KA. Phase Solubility Techniques. Adv Anal Chem Instrum 1965;4:117-212.
15. Mosher G, Thompson DO. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. 2nd ed. Vol. 1. New York: Marcel Dekker, 2002. p. 534.
16. Corrigan OI, Stanley T. Mechanism of drug dissolution rate enhancement from β-cyclodextrin-drug systems. J Pharm Pharmacol 1982;34:621-6.